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Abstract 
  
Background: Clinical decision and patient care management in inflammatory bowel diseases is 
largely based on the assessment of clinical symptoms, while the biomarkers currently in use 
poorly reflect the actual disease activity. Therefore, the identification of novel biomarkers will 
serve an unmet clinical need for IBD screening and patient management. We examined the utility 
of circulating microRNAs for diagnosis and disease activity monitoring in ulcerative colitis (UC) 
patients. 
Methods: Blood serum microRNAs were isolated from UC patients with active and inactive 
disease and healthy donors. High-throughput microRNA profiling was performed using the 
Nanostring technology platform. Clinical disease activity was captured by calculating the partial 
Mayo score. C-reactive protein (CRP) was measured in UC patients as part of their clinical 
monitoring.  The profiles of circulating microRNAs and CRP were correlated with clinical disease 
indices.   
Results: We have identified a signature of 12 circulating microRNAs that differentiate UC patients 
from control subjects. Moreover, six of these microRNAs significantly correlated with UC disease 
activity. Importantly, a set of four microRNAs (hsa-miR-4454, hsa-miR-223-3p, hsa-miR-23a-3p, 
and hsa-miR-320e) which correlated with UC disease activity, were found to have higher 
sensitivity and specificity values than CRP.  
Conclusions: Circulating microRNAs provide a novel diagnostic and prognostic marker for UC 
patients. The use of an FDA approved platform could accelerate the application of microRNA 
screening in a GI clinical setting. When used in combination with current diagnostic and disease 
activity assessment modalities, microRNAs could improve both IBD screening and care 
management.  
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Introduction 
 
Inflammatory bowel diseases (IBD), consisting primarily of ulcerative colitis (UC) and Crohn’s 
disease (CD), are chronic idiopathic pathological conditions characterized by frequent 
inflammatory episodes in the gastrointestinal track.1, 2  The prevalence of IBD around the world 
varies substantially with the higher prevalence recorded in Europe and the United States.3  
Moreover there is an increasing manifestation of IBD in the developing countries.3 In the United 
States the prevalence of pediatric CD and UC is approximately 43 and 28 per 100,000 individuals, 
respectively.4  In adults, the corresponding numbers are 201 and 238 per 100,000 individuals.4  
Overall in the United States approximately more than one million people suffer today from IBD.5  
Current clinical decisions in IBD are based on clinical examinations and assessment of 
symptoms resulting in disease activity indices, in combination with histopathology, endoscopy, 
and imaging techniques.6  Evaluating IBD disease activity from clinical indices is often inaccurate 
due to the subjective recording of symptoms.7  Additionally, most of the imaging techniques are 
invasive, painful, time-consuming and expensive causing significant burden on the patient.  To 
overcome the above challenges a number of biomarkers is routinely applied in combination to the 
above methods to facilitate diagnosis and assess disease activity.8  Most commonly applied IBD 
biomarkers include fecal proteins calprotectin and lactoferin9 and serological proteins such as C-
reactive protein (CRP). CRP is a liver-derived protein that is produced in acute response to 
various inflammatory stimuli.10  Although CRP correlates with IBD disease activity it shows low 
specificity and high expression heterogeneity in CD and UC patients.11-13  Fecal biomarkers 
correlate with IBD disease activity and relapse but harvesting feces samples is a hurdle for IBD 
patients.8, 9, 14  Thus even nowadays, diagnosis and management of IBD remain challenging to 
the most experienced physicians.  Therefore, the identification of novel, accurate non-invasive 
IBD biomarkers to monitor disease activity would serve an unmet medical need.   
MicroRNAs are small (18-25 nucleotides) non-coding RNA molecules that act as negative 
regulators of gene expression at the post-translational level.15  Several studies have 
demonstrated differential microRNA expression patterns between healthy and diseased 
individuals particularly for cancer,16 cardiovascular17 and inflammatory diseases18, 19 including UC 
and CD.20, 21  Emerging evidence suggests that microRNAs can be found in serum and plasma 
as well as urine, at stable, reproducible and consistent expression levels.22, 23  Additionally, recent 
studies have correlated the expression levels of circulating microRNAs with disease diagnosis 
and clinical outcomes.24, 25   
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The purpose of our study was to evaluate the potential of serum microRNAs as diagnostic 
and disease activity assessment tools in adult patients of UC. We have employed the Nanostring 
platform technology to perform microRNA expression profiling in serum samples of active and 
inactive UC patients and healthy controls. We have identified a microRNA gene signature that 
discriminates between healthy and UC and correlates with the respective disease activity index. 
This is the first report on a set of circulating microRNAs that correlate and can be reliably 
employed to assess disease activity in UC.   
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Materials and methods 
 
Blood samples: Whole blood from UC patients and healthy donors (IRB#12-000420) was 
subjected to serum and peripheral blood mononuclear cells (PBMCs) isolation by centrifugation 
(1600g, 15 minutes, 4oC) and Ficoll (Roche) gradient centrifugation (1600g, 10 minutes, 4oC), 
respectively.  
 
Partial Mayo index 
Partial mayo index was calculated by the treating physician at every clinical visit based on 
assessment of stool frequency, rectal bleeding, and physician’s global assessment. Every 
parameter was estimated on a scale from 0 to 4 as previously described.26 Based on the partial 
Mayo index UC patients were categorized in remission (≤2), moderately active (3-4), severely 
active (≥5).  
 
CRP measurements 
C-reactive protein (CRP) detection in blood serum samples was performed in the main clinical 
laboratory of the Ronald Reagan Medical school of University of California, Los Angeles (UCLA). 
Venus blood was collected in yellow top BD Microtainer Laboratory Plastic Capillary Blood 
Collectors supplemented with Clot additive. Approximately, 1 mL of venous blood (0.5 mL serum) 
was used for the detection of CRP via nephelometry. The reference range of the detection method 
is <0.8 mg/dL. 
 
RNA isolation 
RNA was isolated from serum samples using the miRNeasy Serum/Plasma Kit (Qiagen) and from 
PBMCs with the miRCURY Cell and Plant RNA Isolation Kit (Exiqon) according to the 
manufacturer’s instructions. Eluted RNA from serum samples and PBMCs was further purified 
and concentrated by using Amicon Ultra YM-3 columns (3000 kDa MWCO, Millipore). 
 
Nanostring analysis 
RNAs following hybridization reactions were processed using the nCounter Prep Station and 
subsequently the nCounter Digital Analyzer and analyzed by nSolver software, v1.1 (Nanostring 
Technologies). Normalization was performed using all the microRNAs with coefficient of variation 
less than 70%. 
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Statistical analysis 
Statistical analyses were performed with the use of Origin software, version 8.6. Student's t-test 
was used to examine the statistical difference in microRNA levels between control samples and 
specimens derived from active and inactive UC patients. The correlation significance was 
determined by means of Spearman correlation analyses. A P value of 0.05 or less was considered 
to indicate statistical significance. The ROC curves were generated using ROCR package 
(http://rocr.bioinf.mpi-sb.mpg.de/ROCR.pdf) in R/Bioconductor. Area under the curve and its 
significance was calculated using the ‘verification’ package (http://cran.r-
project.org/web/packages/verification/verification.pdf). Linear regression analysis using both 
CRP and microRNAs as independent variables and the partial Mayo score as the dependent 
variable to determine whether both measures contributed redundantly or synergistically to the 
prediction of disease severity. Regression analyses were conducted using PASW Statistics 
21, Release Version 21.0.0 (SPSS, Inc.). 
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Results 
 
Identification of a Serum MicroRNA Signature for UC patients 
To identify microRNAs with potential diagnostic value, we performed microRNA profiling analysis 
using the Nanostring Technology platform and compared the levels of microRNAs expressed in 
the serum of healthy controls (n=21) relative to UC patients (n=46).  The clinical characteristics 
of patient groups and healthy controls are presented in Table 1. This approach revealed 12 
microRNAs to be differentially expressed between control and UC patients (Figure 1A). 
Specifically, 9 microRNAs were up-regulated (miR-223a-3p, miR-23a-3p, miR-302-3p, miR-191-
5p, miR-22-3p, miR-17-5p, miR-30e-5p, miR-148b-3p, miR-320e) and 3 were down-regulated 
(miR-1827, miR-612, miR-188-5p) in UC patient vs control serum samples (Figure 1B).  
 
Identification of a Serum MicroRNA Signature correlated with UC Disease Activity 
To identify microRNAs that correlate with UC disease activity we performed microRNA profiling 
analysis in serum samples derived from UC active (n=24) and inactive (in remission) (n=22) 
patients. This approach revealed six microRNAs (miR-4454, miR-223-3p, miR-23a-3p, miR-148b-
3p, miR-320e and miR-4516) significantly down-regulated in UC patients in remission relative to 
patients with active disease (Figure 2A). Analysis of the CRP, by using a nephelometry assay, 
revealed lower levels of CRP in inactive UC patients compared to active (Figure 2B) and 
calprotectin (Supplementary Figure 1) however neither reached statistical significance.   
 
Subsequently, we investigated the correlation between the microRNA levels and the partial Mayo 
score, a well-established disease activity index for UC. UC patients were clustered according to 
their partial Mayo scores in three groups: a) patients in remission (n=22); b) patients with 
moderately active disease (n=10) and c) patients with severely active disease (n=14). The levels 
of miR-223-3p, miR-4454, miR-23a-3p, miR-148b-3p, miR-320e and miR-4516 positively 
correlated with disease severity (Figure 3A). Five microRNAs (with the exception of miR-148b-
3p, Supplementary Figure 2) were significantly higher in severely active UC patients in 
comparison to inactive patients. However, the difference between patients in remission and 
moderately active patients did not reach statistical significance. Most importantly, the CRP levels 
did not exhibit statistically significant differences between any of the same groups of UC patients 
(Figure 3B), suggesting that microRNA analysis consists a more reliable means in monitoring 
disease activity than CRP. 
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To compare the diagnostic value of the identified microRNAs we plotted their levels against the 
disease activity index or CRP. As shown in Figure 4A four microRNAs correlated significantly 
with the partial Mayo score of active and inactive UC patients (Supplementary Figure 3). 
However, CRP levels failed to reach significant correlation with the partial Mayo score (Figure 
4B). Importantly, all microRNAs demonstrated a higher Spearman r value in comparison to CRP 
indicative of the higher correlation to the partial Mayo score than CRP. To the best of our 
knowledge this is the first demonstration of significant correlation between levels of circulating 
microRNAs and disease activity in UC. In accord, the above data propose that serum derived 
microRNAs might hold superior prognostic value than CRP.   
 
Sensitivity and Specificity Analysis of the Serum UC MicroRNA Signature 
In order to further explore the performance of the identified microRNA signature as disease 
activity biomarkers we calculated the specificity and sensitivity of each microRNA as well as of 
their combination. As benchmark we used CRP, for which we calculated the sensitivity and 
specificity in the UC patients. Sensitivity describes the ability of the test to identify correctly true 
positives, in this case patients with active disease as indicated by the disease activity index. On 
the other hand specificity, describes the predictive ability of the test to identify true negatives, 
which are patients in remission as indicated by the partial Mayo score. The threshold value for 
CRP to distinguish active from inactive IBD patients is 0.8 mg/mL as indicated by the guidelines 
of the UCLA Clinical Laboratory and Pathology Services 
(https://online.lexi.com/lco/action/doc/retrieve/docid/ucla/86972). By applying the above 
threshold we calculated that the sensitivity and specificity of CRP method for UC is 37% and 95% 
respectively (Figure 5A). In order to find the best threshold value of each microRNA we generated 
a receiver operating characteristics (ROC) curve by applying a R statistical package called 
“verification”. The sensitivity and specificity of miR-4454, miR-223-3p, miR-23a-3p, and miR-320e 
are 70%-68%, 79%-72%, 79%-68%, and 67%-67% (Supplementary Figure 4), respectively. 
Among all combinations of microRNAs the one with the highest sensitivity (78%) and specificity 
(81%) was the one of combining all four microRNAs (Figure 5B). This is the first comparison 
between serum microRNAs and CRP as disease activity biomarkers in IBD. The above data 
suggest that the analysis of the four circulating microRNAs provides superior sensitivity and 
comparable specificity to CRP for the detection of active UC.  
 
Predictive values of Serum microRNAs and CRP in UC patients 
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To compare the utility of microRNAs and CRP independently or in combination to reflect disease 
severity we conducted a linear regression analysis. We used both CRP and microRNAs as 
independent variables and the partial Mayo score as the dependent variable. Simple regression 
analysis revealed that disease severity, as measured by partial Mayo score, is predicted by both 
microRNAs (r=0.56, p<0.01) and CRP (r=0.09, p<0.59). Importantly, using multiple linear 
regression, when both microRNAs and CRP were entered into a single prediction model, the CRP 
no longer reflected disease severity. In fact, when removing the common variance shared by 
microRNAs and CRP, microRNAs became the only significant predictor of disease severity, 
accounting for a total of 38% of its variance. These analyses suggest that the 
predictive/prognostic use of CRP is covered by the microRNAs. Furthermore, these results show 
that using both variables to predict the severity of disease provides no additional information than 
the measurement of microRNAs alone.  
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Discussion 
 
The detection of blood circulating microRNAs has opened new avenues in the development of 
diagnostic and prognostic biomarkers for different human diseases, including inflammatory 
diseases.22 Previous studies have performed microRNA analysis in different blood fractions 
(serum, plasma, PBMCs) or in whole blood and have identified different microRNA signatures 
involved with different clinicopathological parameters in human diseases.27, 28 Interestingly, the 
microRNA profiles between serum and plasma have been very similar, suggesting that both 
fractions can be used for evaluation of circulating microRNAs.22 Our aim in this study was to 
evaluate if circulating microRNAs could have diagnostic and/or prognostic value for UC patients 
relative to well-known biomarkers such as CRP and the Mayo score.  
 
A major issue to potentially develop a diagnostic and/or prognostic microRNA blood test is the 
identification of the appropriate method of normalization for the microRNA expression levels. 
Different microRNA array technologies use different microRNAs for normalization, thus the data 
depend on each technology and cannot be easily compared. Importantly, there are no microRNAs 
or other small RNAs in serum samples have been shown to be preserved at abiding levels among 
different samples, suggesting the lack of standard ‘housekeeping’ genes. In fact, the use of 
housekeeping genes (such as actin or U6) in analyses of serum samples would rather reflect the 
presence or sample contamination with lysed blood cells. Thus, the traditional reference genes 
can be used not as standards but could serve as a quality control indicator to exclude samples 
with hemolysis. In addition, the inclusion of a spike-in RNA can rather serve as an internal control 
for monitoring the efficiency/consistency of microRNA isolation from serum samples than a 
reference gene. Therefore, here normalization was performed to the global levels of microRNAs 
present in the serum samples. A second important parameter is that evaluating the microRNA 
expression levels by PCR analysis or microarray analysis involves an amplification step that 
actually affects the outcome (microRNA levels). To evaluate the levels of microRNAs and limit the 
effects of the amplification step, we have used novel technology, called Nanostring technology, 
which recently received an FDA clearance 
(http://www.nanostring.com/company/corp_press_release?id=93). In this study, our findings fulfill 
these important criteria, pointing to the potential use of these UC microRNA signatures as 
diagnostic and/or prognostic tools in the clinic.  
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In the current study we report the identification of a panel of serum microRNAs as novel 
biomarkers of UC disease activity. Given the recent IBD prevalence data, there is an unmet 
medical need for improved assessment of disease activity and detection of early response to 
applied therapies. These goals should be reached in combination with decrease in the costs 
associated to the high levels of care utilization. Furthermore, with analyses focused more on 
specific subgroups of patients, the set of serum microRNAs identified here could be tested for its 
utility in patient risk stratification, monitoring disease activity, the timely detection of disease 
flares/relapse and the assessment of drug responses. These applications represent significant 
steps towards a prevention-oriented care medicine, and control of smoldering disease activity. 
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Table I. Demographic and clinical characteristics of healthy controls and UC patients.    
 Control (n=21) UC (n=46) 
 Total F M Total F M 
Gender  62% 38%  39% 61% 
Age (years) 33±8 33±8 35±8 38±12 42±14 36±11 
Disease Duration 0 0 0 8±3 8±6 9±8 
Smoking 21% 16% 28% 11% 11% 11% 
Fistulas 0% 0% 0% 4% 0% 7% 
Strictures 0% 0% 0% 0% 0% 0% 
Surgery 0% 0% 0% 15% 11% 18% 
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Table II. Demographic and clinical characteristics of active and inactive UC patients.    
 Active (N=24) Inactive (N=22) 
 F M F M 
Gender 42% 58% 33% 67% 
Age (yrs) 41±13 34±9 42±15 38±12 
Disease Duration 9±5 6±6 6±6 11±9 
Smoking 0% 14% 25% 7% 
Fistulas 0% 7% 0% 7% 
Strictures 0% 0% 0% 0% 
Surgery 20% 21% 0% 7% 
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Figures 
 
 
Figure 1.  The levels of circulating microRNAs significantly differ in UC patients compared 
to healthy subjects.  A. Heatmap of circulating microRNAs in UC patients (n=46) and healthy 
donors (n=21). The Heatmap represents the relative levels of microRNAs as assessed using the 
Nanostring platform. B. Circulating microRNAs with diagnostic value. Serum microRNAs with 
statistically different levels between healthy donors and UC patients. Data are represented as 
mean values ± s.e.m. * P <0.05, ** P <0.01, Student’s t test. 
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Figure 2. Circulating microRNAs as a prognostic tool. A. Circulating microRNAs with 
prognostic value. Serum microRNAs with statistically different levels between active (N=24) and 
inactive (N=22) UC patients. B. CRP levels in the same patients. Data are represented as mean 
values ± s.e.m. * P <0.05, ** P <0.01, Student’s t test. ns, non significant.  
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Figure 3. Correlation between the levels of circulating microRNAs and UC disease activity. 
A. Circulating microRNAs with prognostic value in UC patients grouped based on the partial Mayo 
score. B. CRP levels in the same patient groups. Data are represented as mean values ± s.e.m. 
Only statistically significant differences are denoted. * P <0.05, ** P <0.01, Student’s t test.   
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Figure 4. Correlation of circulating microRNAs and CRP with partial Mayo score in active 
and inactive UC patients.  A. Spearman correlation analysis of the four microRNAs with 
prognostic value in active and inactive UC patients. B. Spearman correlation analysis of CRP in 
the same patients UC patients. ANOVA (P). 
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Figure 5. Sensitivity and specificity of circulating microRNAs and CRP tests in UC patients. 
A. ROC curve of four prognostic microRNAs (hsa-miR-4454, hsa-miR-223-3p, hsa-miR-23a-3p, 
hsa-miR-320e) combined in UC patients (N=46). B. ROC curve of CRP in the same patients. 
ROC curves were generated by applying the “verification” R statistical package. Values indicate 
the area under the curve and the statistical significance (in parentheses). 
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Figure 6.  Predictive values of microRNAs and CRP in UC patients. A. Scatter plot shows 
that partial Mayo score (y-axis) is predicted by the microRNAs (index of all four microRNAs 
combined) (x-axis), over and above CRP. The x-axis displays the residual variance in the 
microRNAs after partialling out its shared variance with CRP. B. Scatter plot shows that partial 
Mayo score (y-axis) is no longer predicted by the CRP, when the shared variance between the 
CRP and the microRNAs was removed (x-axis). The x-axis displays the residual variance in the 
CRP, after partialling out its shared variance with microRNAs. 
 
